Abstract

Aims

To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events.

Methods and results

Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600).

Conclusions

Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.

Details

Title
Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
Author
Gimeno, Juan R. 1   VIAFID ORCID Logo  ; Olivotto, Iacopo 2   VIAFID ORCID Logo  ; Rodríguez, Ana Isabel 3 ; Ho, Carolyn Y. 4 ; Fernández, Adrián 5 ; Quiroga, Alejandro 5 ; Espinosa, Mari Angeles 6 ; Gómez‐González, Cristina 6 ; Robledo, María 7 ; Tojal‐Sierra, Lucas 7 ; Day, Sharlene M. 8 ; Owens, Anjali 8 ; Barriales‐Villa, Roberto 9   VIAFID ORCID Logo  ; Larrañaga, Jose María 9 ; Rodríguez‐Palomares, Jose 10   VIAFID ORCID Logo  ; González‐del‐Hoyo, Maribel 10 ; Piqueras‐Flores, Jesús 11 ; Reza, Nosheen 8 ; Chumakova, Olga 12 ; Ashley, Euan A. 13 ; Parikh, Victoria 13 ; Wheeler, Matthew 13 ; Jacoby, Daniel 14 ; Pereira, Alexandre C. 15 ; Saberi, Sara 16 ; Helms, Adam S. 16 ; Villacorta, Eduardo 17   VIAFID ORCID Logo  ; Gallego‐Delgado, María 17   VIAFID ORCID Logo  ; Castro, Daniel 18 ; Domínguez, Fernando 18 ; Ripoll‐Vera, Tomás 19   VIAFID ORCID Logo  ; Zorio‐Grima, Esther 20   VIAFID ORCID Logo  ; Sánchez‐Martínez, José Carlos 20 ; García‐Álvarez, Ana 21 ; Arbelo, Elena 21   VIAFID ORCID Logo  ; Mogollón, María Victoria 22 ; Fuentes‐Cañamero, María Eugenia 23 ; Grande, Elias 24 ; Peña, Carlos 24 ; Monserrat, Lorenzo 24   VIAFID ORCID Logo  ; Lakdawala, Neal K. 4 

1  Departamento de Medicina Interna, Universidad de Murcia, Murcia, Spain, European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD‐Heart), Amsterdam, The Netherlands, Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain 
2  Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy 
3  Departamento de Medicina Interna, Universidad de Murcia, Murcia, Spain, European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD‐Heart), Amsterdam, The Netherlands 
4  Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA 
5  Unidad de Cardiopatías Familiares, Favaloro Foundation University Hospital, Buenos Aires, Argentina 
6  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Unidad de Cardiopatías Familiares, Hospital General Universitario Gregorio Marañón, Madrid, Spain 
7  Hospital Universitario Araba (Txagorritxu), Alava, Spain 
8  Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA 
9  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Unidad CSUR Cardiopatías Familiares, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain 
10  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain 
11  Cardiac Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain 
12  Municipal Clinical Hospital #17, Moscow, Russia 
13  Center for Inherited Heart Disease, Stanford University Medical Center, Stanford, CA, USA 
14  Yale New Haven Hospital, New Haven, CT, USA 
15  Hospital das Clinicas da Univerisidade de Sao Paulo, Sao Paulo, Brazil 
16  Department of Internal Medicine, University of Michigan Hospital, Ann Arbor, MI, USA 
17  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, Gerencia Regional de Salud de Castilla y León (SACYL), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain, Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain 
18  European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD‐Heart), Amsterdam, The Netherlands, Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Unidad CSUR/ERN Cardiopatias Familiares, Hospital Universitario Puerta Hierro Majadahonda, Madrid, Spain 
19  Unidad Cardiopatias Familiares, Hospital Universitario Son Llàtzer, Mallorca, Spain 
20  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Unidad Cardiopatias Familiares, Hospital Universitario y Politécnico La Fe, Valencia, Spain 
21  Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain, Arrhythmia Section, Cardiology Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain 
22  Cardiac Department, Hospital San Pedro de Alcantara, Cáceres, Spain 
23  Cardiac Department, Badajoz University Hospital, Badajoz, Spain 
24  Dilemma Solution S.L, A Coruña, Spain 
Pages
2189-2198
Section
Original Articles
Publication year
2022
Publication date
Aug 1, 2022
Publisher
Oxford University Press
e-ISSN
20555822
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1002/ehf2.13964
ProQuest document ID
2690638400
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.